Table 3 Reported adverse events.

From: Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study

Adverse events

LNDL n: 141

MNDL n: 142

ACL n: 71

p value

Abdominal pain

14 (9.93%)

13 (9.15%)

6 (8.45%)

0.937

Nausea

23 (16.31%)

24 (16.9%)

11 (15.49%)

0.966

Vomiting

4 (2.84%)

5 (3.52%)

3 (4.23%)

0.865

Diarrhea

9 (6.38%)

8 (5.63%)

12 (16.9%)

0.011*

Constipation

7 (4.96%)

7 (4.93%)

2 (2.82%)

0.742

Flatulence

11 (7.8%)

11 (7.75%)

7 (9.86%)

0.849

Palpitation

2 (1.42%)

2 (1.41%)

1 (1.41%)

0.999

Headache

8 (5.67%)

9 (6.34%)

10 (14.08%)

0.071

Dizziness

2 (1.42%)

5 (3.52%)

2 (2.82%)

0.525

Discolored urine

16 (11.35%)

11 (7.75%)

1 (1.41%)

0.041*

Skin rash

3 (2.13%)

3 (2.11%)

2 (2.82%)

0.939

  1. Chi square test and Fisher’s exact test were used when appropriate, *Statistically significant.
  2. LNDL: Levofloxacin, nitazoxanide, doxycycline, lansoprazole.
  3. MNDL: Moxifloxacin, nitazoxanide, doxycycline, lansoprazole.
  4. ACL: Amoxicillin, clarithromycin, lansoprazole.
Back to article page